The state-of-the-art commercial production plant will be built on a 95-acre site in Saarlouis, acquired at the end of 2024
The deal brings three high-quality small-molecule drug substance sites into Siegfried’s portfolio
Plant 1 continues to serve as a core manufacturing hub for oral solid dosage forms
Stevens succeeds Milton Boyer, who has stepped down as CEO but will remain closely involved with the business as an independent member of Kindeva’s Board of Directors
The Eugene facility, with more than 20 years of history, houses a 16,000-square-foot R&D lab and a newly constructed 30,000-square-foot manufacturing facility
The updated closure system introduces intuitive handling, innovative functionality and a premium design compatible with a wide range of syringe formats
Nitrosamines have prompted evolving global guidelines that demand rigorous industry oversight
The antibody was designed and developed at Abzena’s Cambridge, UK,
Expanding US operations to address the increased demand for API development and manufacturing
Subscribe To Our Newsletter & Stay Updated
